Literature DB >> 14996716

Insulin-like growth factor (IGF)-binding protein-4 inhibits colony formation of colorectal cancer cells by IGF-independent mechanisms.

Daniela Diehl1, Andreas Hoeflich, Eckhard Wolf, Harald Lahm.   

Abstract

Effects of insulin-like growth factor-binding protein-4 (IGFBP-4) on proliferation, colony formation, and cell migration were assessed in IGF-sensitive and -insensitive colorectal cancer cell lines. In IGF-insensitive Isreco-1 cells, overexpression of IGFBP-4 reduced colony formation but not cell proliferation and migration, whereas exogenous IGF-II had no effect. In IGF-dependent LS1034 cells, IGFBP-4 inhibited all parameters of growth tested, whereas IGF-II partially restored reduced proliferation and cell migration only. In Isreco-2 cells, which lack endogenous IGF expression but are IGF sensitive, colony formation was also reduced by IGFBP-4. Therefore, specific parameters of malignant progression of colon carcinoma cells are distinctly affected by IGF-dependent and IGF-independent effects of IGFBP-4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996716     DOI: 10.1158/0008-5472.can-03-2844

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.

Authors:  M Davies; S Gupta; G Goldspink; M Winslet
Journal:  Int J Colorectal Dis       Date:  2005-06-16       Impact factor: 2.571

Review 2.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

3.  Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I).

Authors:  Friedrich Metzger; Waseem Sajid; Stefanie Saenger; Christian Staudenmaier; Chris van der Poel; Bettina Sobottka; Angelika Schuler; Mandy Sawitzky; Raphael Poirier; Dietrich Tuerck; Eginhard Schick; Andreas Schaubmar; Friederike Hesse; Kurt Amrein; Hansruedi Loetscher; Gordon S Lynch; Andreas Hoeflich; Pierre De Meyts; Hans-Joachim Schoenfeld
Journal:  J Biol Chem       Date:  2011-04-01       Impact factor: 5.157

Review 4.  Functional consequences of IGFBP excess-lessons from transgenic mice.

Authors:  Eckhard Wolf; Marlon R Schneider; Rui Zhou; Thomas M Fisch; Nadja Herbach; Maik Dahlhoff; Rüdiger Wanke; Andreas Hoeflich
Journal:  Pediatr Nephrol       Date:  2004-12-16       Impact factor: 3.714

5.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

6.  IGF-II transgenic mice display increased aberrant colon crypt multiplicity and tumor volume after 1,2-dimethylhydrazine treatment.

Authors:  Daniela Diehl; Doris Oesterle; Martin W Elmlinger; Andreas Hoeflich; Eckhard Wolf; Harald Lahm
Journal:  J Carcinog       Date:  2006-11-21

7.  IGFBP-4 and -5 are expressed in first-trimester villi and differentially regulate the migration of HTR-8/SVneo cells.

Authors:  Erin J Crosley; Caroline E Dunk; Alexander G Beristain; Julian K Christians
Journal:  Reprod Biol Endocrinol       Date:  2014-12-04       Impact factor: 5.211

Review 8.  Current IGFBP-Related Biomarker Research in Cardiovascular Disease-We Need More Structural and Functional Information in Clinical Studies.

Authors:  Andreas Hoeflich; Robert David; Rikke Hjortebjerg
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-16       Impact factor: 5.555

9.  IGFBP-4: A promising biomarker for lung cancer.

Authors:  Savas Irem Nur; Akin Ozturk; Murat Kavas; Ismet Bulut; Sumeyye Alparslan; Eroglu Selma Aydogan; Baytemir Cansel Atinkaya; Murat Kolay; Abdurrahman Coskun
Journal:  J Med Biochem       Date:  2021-06-05       Impact factor: 3.402

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.